Recurrent Disease Completed Phase 1 / 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01445080Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaTreatment